


### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims**

12. (currently amended) A compound of formula (I):



wherein:

Ar is phenyl which can be optionally substituted by one or more groups selected from halogen, hydroxy, cyano, C<sub>1</sub>-C<sub>8</sub> alkyl (itself optionally substituted by one or more hydroxy or cyano groups or fluorine atoms), CH<sub>2</sub>-R<sup>2</sup>[[.]] ± CH<sub>2</sub>O(CH<sub>2</sub>)<sub>n</sub>OC<sub>1-6</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkyl-NR<sup>3</sup>-R<sup>4</sup>;

R<sup>2</sup> is a 5 to 7-membered saturated ring containing 1 or 2 heteroatoms selected from nitrogen, oxygen and sulphur, an aryl or 5- to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from nitrogen oxygen and sulphur, each of which can optionally substituted by one or more substituents selected from hydroxyl or hydroxymethyl;

R<sup>3</sup> is hydrogen or C<sub>1-6</sub> alkyl and R<sup>4</sup> is C<sub>1-6</sub> alkyl optionally substituted by one or more groups selected from hydroxyl or phenyl,

n is 1 to 4;

R<sup>1</sup> is hydrogen or phenyl optionally substituted by halogen, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> thioalkyl or C<sub>1</sub>-C<sub>8</sub> alkyl;

and ~~pharmaceutically acceptable salts~~ a pharmaceutically acceptable salt thereof.

13. (currently amended) A compound according to claim 12 in which R<sup>1</sup> is hydrogen, ~~or~~  
~~phenyl optionally substituted by halogen.~~

14. (currently amended) A compound according to claim 12 in which Ar is a phenyl ~~or a~~  
~~group optionally substituted by one or more~~ CH<sub>2</sub>R<sup>2</sup> groups, where R<sup>2</sup> is pyrrolidine, morpholine  
or imidazole each of which is optionally substituted as defined in claim 12.

15. (currently amended) A compound according to claim 12 in which Ar is a ~~group~~ phenyl  
optionally substituted by one or more CH<sub>2</sub>R<sup>2</sup> groups where R<sup>2</sup> is pyrrolidine, morpholine or  
imidazole each of which is optionally substituted by hydroxyl or hydroxymethyl, ~~or Ar is a phenyl~~  
optionally substituted by one or more CH<sub>2</sub>NR<sup>3</sup>-R<sup>4</sup> groups where R<sup>3</sup> is hydrogen or methyl and R<sup>4</sup>  
is CH<sub>2</sub>CH<sub>2</sub>OH, CH<sub>2</sub>(CH<sub>3</sub>)CH<sub>2</sub>OH, CH<sub>2</sub>(phenyl)CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>(OH)phenyl, CH<sub>2</sub>CH<sub>2</sub>(OH)CH<sub>2</sub>OH,  
~~or Ar is a phenyl optionally substituted by one or more~~ CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>OH groups, ~~or Ar is a~~  
phenyl optionally substituted by one or more ethyl or hydroxymethyl groups.

16. (currently amended) A compound according to claim 12 in which the Ar ~~group~~ is phenyl  
substituted by C<sub>1</sub>-C<sub>8</sub> alkyl and C<sub>1</sub>-C<sub>8</sub> alkyl substituted by a hydroxy group, ~~more preferably~~  
hydroxymethyl.

17. A compound according to claim 12 which is:

4-(2-Ethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-(4-fluorophenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-  
carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-  
*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-[(2-hydroxy-ethyl)-methyl-amino]-methyl)-phenylamino)-2-(4-fluoro-phenyl)-1*H*-  
pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-1-methyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-  
pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(*S*)-(2-hydroxy-1-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-  
pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{2-Ethyl-3-[(2-hydroxy-2-phenyl-ethylamino)-methyl]-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-morpholin-4-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[2-Ethyl-3-(3-hydroxy-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[2-Ethyl-3-((*R*)-2-hydroxymethyl-pyrrolidin-1-ylmethyl)-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-{3-[(2,3-Dihydroxy-propylamino)-methyl]-2-ethyl-phenylamino}-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-imidazol-1-ylmethyl-phenylamino)-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-[3-(2-Ethoxy-ethoxymethyl)-2-ethyl-phenylamino]-2-(4-fluoro-phenyl)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Bromo-phenyl)-4-(2-ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-3-hydroxymethyl-phenylamino)-2-phenyl-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Chloro-phenyl)-4-(2-ethyl-3-hydroxymethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

2-(4-Chloro-phenyl)-4-(2-ethyl-3-imidazol-1-ylmethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide

4-(2-Ethyl-phenylamino)-1*H*-pyrrolo[2,3-*b*]pyridine-5-carboxylic acid amide  
or a pharmaceutically acceptable salt thereof.


18. (previously presented) A compound of formula (I) as defined in claims 12 for use in therapy.

19. (previously presented) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 12 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.

20. (currently amended) A method of treating ~~a disease or condition~~ asthma mediated by JAK3 which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I) as defined in claims 12 or a pharmaceutically acceptable salt thereof.

21. (cancelled)

22. (previously presented) A process for the preparation of a compound of formula (I) as defined in claim 12 which comprises:  
reaction of a compound of formula (II):



(II)

in which R<sup>1</sup> is as defined in formula (I) or is a protected derivatives thereof and L is a leaving group, with a compound of formula (III):

Ar-NH<sub>2</sub> (III)

in which Ar is as defined in formula (I) or is a protected derivatives thereof,  
and optionally thereafter:

- removing any protecting groups
- converting a compound of formula (I) into a further compound of formula (I)
- forming a pharmaceutically acceptable salt.

23. (New) A compound according to claim 12 in which R<sup>1</sup> is hydrogen or phenyl optionally substituted by fluoro or bromo.

24. (New) A compound according to claim 12 in which the Ar is phenyl substituted by C<sub>1</sub>-C<sub>8</sub> alkyl and hydroxymethyl.